GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (NAS:CRBP) » Definitions » 5-Year Yield-on-Cost %

CRBP (Corbus Pharmaceuticals Holdings) 5-Year Yield-on-Cost % : 0.00 (As of Mar. 26, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Corbus Pharmaceuticals Holdings 5-Year Yield-on-Cost %?

Corbus Pharmaceuticals Holdings's yield on cost for the quarter that ended in Dec. 2024 was 0.00.


The historical rank and industry rank for Corbus Pharmaceuticals Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:



CRBP's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.6
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Corbus Pharmaceuticals Holdings's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corbus Pharmaceuticals Holdings's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's 5-Year Yield-on-Cost % falls into.



Corbus Pharmaceuticals Holdings 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Corbus Pharmaceuticals Holdings is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Corbus Pharmaceuticals Holdings  (NAS:CRBP) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Corbus Pharmaceuticals Holdings 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Corbus Pharmaceuticals Holdings Business Description

Traded in Other Exchanges
Address
500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Executives
Yuval Cohen director, officer: Chief Executive Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Sean F. Moran officer: Chief Financial Officer 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Yong Ben director 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Anne Altmeyer director 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Craig Stuart Millian officer: Chief Commercial Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Rachael Louise Brake officer: Chief Scientific Officer 21 MANCHESTER PLACE, NATICK MA 01760
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Peter Salzmann director 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Barbara White officer: Chief Medical Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Paul Discordia officer: Chief Operating Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
David P Hochman director 15 WESTON HILL RD., RIVERSIDE CT 06878
John Kenneth Jenkins director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Paris Panayiotopoulos director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Avery W Catlin director 241 CENTRAL STREET, HINGHAM MA 02043